IP Library Patent Application 17438810
Patent Application
App. No. 17/438,810

MICROBIAL PRODUCTION OF COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/438,810
Abstract

Provide are modified host cells that are engineered to decrese expression of a product to undetectable levels in the presence of an exogenous agent, and increase expression of the product in the presence of another exogenous agent. The modified yeast strainshost cells do not express detectable levels of a precursor or substrate used to make the product. The product can be a cannabinoid or precursor thereof, and the substrate can be hexanoate. Also provided are methods for making a product using the modified host cells. The modified host cell can be a yeast strain, such as S. cerevisiae.

Claims (49)

1 . A host cell comprising a heterologous genetic pathway that produces a heterologous product and that is regulated by an exogenous agent, wherein the host cell does not produce a precursor required to make the product.

2 . The host cell of claim 1 , wherein the exogenous agent comprises a regulator of gene expression.

3 . The host cell of claim 2 , wherein the exogenous agent decreases production of the heterologous product, or wherein the exogenous agent is glucose and expression of one or more enzymes encoded by the heterologous genetic pathway are under control of a glucose repressed promoter.

4 . (canceled)

5 . The host cell of claim 2 , wherein the exogenous agent increases production of the heterologous product, or wherein the exogenous agent is galactose and expression of one or more enzymes encoded by the heterologous genetic pathway are under control of a GAL promoter.

6 . (canceled)

7 . The host cell of claim 1 , wherein the heterologous genetic pathway comprises a galactose-responsive promoter, a maltose-responsive promoter, or a combination of both, or the heterologous product is a cannabinoid or cannabinoid precursor, wherein the cannabinoid or cannabinoid precursor is CBDA, CBD, CBGA, or CBG.

8 . (canceled)

9 . (canceled)

10 . The host cell of claim 7 , wherein the genetic pathway encodes at least two enzymes selected from the group consisting of hexanoyl-CoA synthase (HCS), tetraketide synthase (TKS) and olivetolic acid cyclase (OAC).

11 . The host cell of claim 1 , wherein the precursor required to make the product is hexanoate, olivetol, or olivetolic acid.

12 . The host cell of claim 1 , wherein the heterologous genetic pathway comprises a nucleic acid construct comprising at least 3 protein coding regions.

13 . The host cell of claim 1 , wherein the host cell is a yeast cell or yeast strain, or the host cell is S. cerevisiae.

14 . (canceled)

15 . A mixture comprising the host cell of claim 1 and a culture media.

16 . The mixture of claim 15 , wherein the culture media comprises an exogenous agent that decreases production of the heterologous product, or wherein the culture media comprises glucose, maltose, or lysine.

17 . (canceled)

18 . The mixture of claim 15 , wherein the culture media comprises (i) an exogenous agent that increases production of the heterologous product, and (ii) a precursor required to make the heterologous product, or the culture media comprises galactose and hexanoate.

19 . (canceled)

20 . (canceled)

21 . A method for decreasing the expression of a heterologous product, comprising culturing the host cell of claim 1 in a media comprising an exogenous agent, wherein the exogenous agent decreases the expression of the heterologous product, or the media comprises glucose, maltose, or lysine, or wherein culturing the host cell in the media comprising the exogenous agent results in less than 0.001 mg/L of heterologous product.

22 . (canceled)

23 . (canceled)

24 . A method for increasing the expression of a heterologous product, comprising (i) culturing the host cell of claim 1 in a media comprising the exogenous agent, wherein the exogenous agent increases expression of the heterologous product, or (ii) culturing the host cell of claim 1 in a media comprising galactose.

25 . (canceled)

26 . The method of claim 24 , further comprising (i) culturing the host cell with the precursor required to make the heterologous product, or (ii) culturing the host cell with hexanoate.

27 . (canceled)

28 . A host cell comprising a heterologous genetic pathway that produces a cannabinoid and is regulated by an exogenous agent, wherein the host cell does not comprise hexanoate at a level to make the cannabinoid in an amount over 10 mg/L.

29 . The host cell of claim 28 , wherein (i) the exogenous agent downregulates expression of the heterologous genetic pathway, or

(ii) the exogenous agent is glucose and expression of one or more enzymes encoded by the heterologous genetic pathway are under control of a glucose repressed promoter; or

(iii) the exogenous agent upregulates expression of the heterologous genetic pathway, or

(iv) the exogenous agent is galactose and expression of one or more enzymes encoded by the heterologous genetic pathway are under control of a GAL promoter; or

(v) wherein the genetic pathway encodes at least two enzymes selected from the group consisting of hexanoyl-CoA synthase (HCS), tetraketide synthase (TKS) and olivetolic acid cyclase (OAC); or

(vi) the host cell is a yeast cell or yeast strain, or the host cell is S. cerevisiae.

30 . (canceled)

31 . (canceled)

32 . (canceled)

33 . (canceled)

34 . (canceled)

35 . (canceled)

36 . A method for decreasing expression of a cannabinoid, comprising (i) culturing the host cell of claim 28 in a media comprising the exogenous agent, wherein the exogenous agent decreases the expression of the cannabinoid or a precursor thereof; or (ii) culturing the host cell of claim 28 in a media comprising glucose, maltose, or lysine; wherein culturing the host cell in the media comprising the exogenous agent results in less than 0.001 mg/L of cannabinoid or a precursor thereof.

37 . (canceled)

38 . (canceled)

39 . A method for increasing expression of a cannabinoid, comprising (i) culturing the host cell of claim 28 in a media comprising the exogenous agent, wherein the exogenous agent increases the expression of the cannabinoid or a precursor thereof; or (ii) culturing the host cell of claim 28 in a media comprising galactose.

40 . (canceled)

41 . The method of claim 39 , further comprising culturing the host cell in a media comprising hexanoate.

42 . The method of claim 36 , wherein the cannabinoid is CBDA, CBD, CBGA, or CBG.

43 . The method of claim 36 , wherein the host cell is a yeast cell or yeast strain, or the host cell is S. cerevisiae.

44 . (canceled)

Assignments (5)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2022
From: REEVES, CHRISTOPHER D.; PADDON, CHRISTOPHER J.; HOLMES, VICTOR F.; KLEIN, ANDREW P.
To: AMYRIS, INC.
Reel/Frame 061801/0617 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →